NEW YORK (GenomeWeb) – A new report filed with German healthcare regulators currently sees no benefit from gene expression-based breast cancer tests used in breast cancer treatment decisions.
Submitted on Oct. 31, 2016 by the Institute for Quality and Efficiency in Healthcare (IQWiG) — a contractor for the German government that evaluates new medical interventions — the report became publicly available last month.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
